Exhaled nitric oxide monitoring does not improve on guidelines-based asthma management

Sep 19, 2008

Exhaled nitric oxide serves as a biomarker of inflammation in the lungs, and proponents have suggested that monitoring nitric oxide levels could help improve management of asthma. However, new research, which will be published in the Sept. 20 issue of The Lancet, indicates that adolescent and young adult patients whose asthma is managed according to the latest NIH guidelines do not benefit from the addition of nitric-oxide monitoring.

"While nitric-oxide monitoring did not improve asthma management, the good news is that most patients can bring their asthma under control by following NIH guidelines which are based on relatively easy-to-measure symptoms and lung function," said Stanley Szefler, MD, lead author of the study and Head of Pediatric Clinical Pharmacology at National Jewish Health.

Asthma is a complex respiratory disorder in which airway inflammation and "twitchy" muscles surrounding the airways can make breathing difficult. Anti-inflammatory corticosteroids are the most effective controller medication for asthma. Nitric oxide is a biomarker of inflammation in the lungs. The researchers hypothesized that monitoring of nitric oxide might help detect patients with ongoing inflammation who needed additional medications to achieve full asthma control.

The researchers, from ten institutions in the National Institutes of Allergy and Infectious Disease's Inner City Asthma Consortium, evaluated two treatment regimens for 546 patients ages 12 -20 with persistent asthma. The patients all came from inner city neighborhoods with at least 20 percent of the population living below the federal poverty level.

All patients completed a three-week run-in period on a standard asthma treatment regimen based upon previous treatment, adherence to medications and asthma control. They were then randomized to either treatment based on NIH Guidelines for the Diagnosis and Management of Asthma or the guidelines plus nitric-oxide monitoring. The NIH guidelines recommended treatment levels based upon measures of days with symptoms in the preceding two weeks and lung-function testing. Nitric-oxide monitoring incorporated those guidelines but physicians could increase medications more than the guidelines called for if NO levels were high. Patients visited physicians every six to eight weeks at which time they were evaluated and treatment adjusted. The trial lasted 46 weeks.

The most significant improvements in asthma symptoms and levels of exhaled nitric oxide occurred during the three-week run in period. At enrollment 77 percent of patients did not have good control of their asthma. By the end of the run-in period 70 percent did have good control of their asthma. Those levels remained similar, ranging between 71 percent and 78 percent with good asthma control throughout the treatment period for all patients.

During the trial the mean number of days with asthma symptoms and pulmonary function were similar in the two groups. Admissions to the hospital, unscheduled use of healthcare, or asthma exacerbations also did not differ between groups. The nitric-oxide monitoring patients did have fewer bursts of oral steroids, a weeklong treatment for more severe asthma symptoms.

Although nitric-oxide monitoring did not make a difference in asthma management overall, post hoc analysis suggested that some subgroups may benefit from nitric-oxide monitoring. Obese patients and highly allergic patients had better control with nitric-oxide monitoring.

"Although nitric-oxide monitoring did not improve overall asthma management, we believe it may still be a useful tool for subsets of patients and in specific circumstances, such as asthma diagnosis, measuring response to inhaled corticosteroid therapy, assessing adherence to corticosteroid therapy, and the safe reduction of inhaled corticosteroid therapy," said Dr. Szefler.

Source: National Jewish Medical and Research Center

Explore further: Doctors urge meningitis shots for vulnerable infants, children

add to favorites email to friend print save as pdf

Related Stories

Greater granularity on anthropogenic emission

Jun 13, 2014

Improved estimates of anthropogenic emissions contribute to better overall air quality forecasts, thus allowing people to manage health conditions associated with air cleanliness.

Privacy issues shadow medical apps' claims to improve care

Sep 02, 2013

Smartphones and tablets are go-to gadgets to count calories, document daily jogs, measure heart rates and record sleep patterns. Some applications now even analyze blood sugar levels, track fertility or monitor moods for ...

Physical by smartphone becoming real possibility

May 03, 2013

It's not a "Star Trek" tricorder, but by hooking a variety of gadgets onto a smartphone you could almost get a complete physical - without the paper gown or even a visit to the doctor's office.

Wireless 'tooth tattoo' detects harmful bacteria

May 30, 2012

Using silk strands pulled from cocoons and gold wires thinner than a spider's web, researchers at Princeton University have created a removable tattoo that adheres to dental enamel and could eventually monitor ...

Recommended for you

$1,000 pill now hepatitis C treatment of choice

6 hours ago

(AP)—A $1,000-per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Swan
not rated yet Jun 18, 2009
In response to this view, I have a set of arguments in favour to Exhaled nitric oxide.

As quoted in recent research they found that using Exhaled nitric oxide is an effective way to monitor asthma. I have come across medical journals, which states that Measuring Nitric Oxide (NO) from the breath (during exhalation) has proven to be a useful tool for some asthma specialists in the U.S. and other parts of the world. An expert from a journal is given below.

Results and Conclusions from New England Journal of Medicine on Use of Exhaled Nitric Oxide Measurements to Guide Treatment in Chronic Asthma.

Results

Forty-six patients in the FeNO group and 48 in the group whose asthma was treated according to conventional guidelines (the control group) completed the study. The final mean daily doses of fluticasone, the inhaled corticosteroid that was used, were 370 %u03BCg per day for the FeNO group (95 percent confidence interval, 263 to 477) and 641 %u03BCg per day for the control group (95 percent confidence interval, 526 to 756; P=0.003), a difference of 270 %u03BCg per day (95 percent confidence interval, 112 to 430). The rates of exacerbation were 0.49 episode per patient per year in the FeNO group (95 percent confidence interval, 0.20 to 0.78) and 0.90 in the control group (95 percent confidence interval, 0.31 to 1.49), representing a non-significant reduction of 45.6 percent (95 percent confidence interval for mean difference, ¡78.6 percent to 54.5 percent) in the FeNO group. There were no significant differences in other markers of asthma control, use of oral prednisone, pulmonary function, or levels of airway inflammation (sputum eosinophils).

Conclusions

With the use of FeNO measurements, maintenance doses of inhaled corticosteroids may be significantly reduced without compromising asthma control.